MCID: FBR002
MIFTS: 47

Fibrosarcoma of Bone

Categories: Bone diseases, Cancer diseases, Immune diseases

Aliases & Classifications for Fibrosarcoma of Bone

MalaCards integrated aliases for Fibrosarcoma of Bone:

Name: Fibrosarcoma of Bone 12 15
Malignant Histiocytosis 12 54 70
Nasal Type Extranodal Nk/t-Cell Lymphoma 70
Histiocytic Medullary Reticulosis 70
Malignant Fibrous Histiocytoma 70
Malignant Fibroxanthoma 12
Histiocytic Sarcoma 70

Classifications:



External Ids:

Disease Ontology 12 DOID:3354
UMLS 70 C0019623 C0334463 C0334663 more

Summaries for Fibrosarcoma of Bone

Disease Ontology : 12 A bone sarcoma characterized by a herringbone or fascicular disposition of atypical, monomorphic fibroblasts and is always negative for any specific marker.

MalaCards based summary : Fibrosarcoma of Bone, also known as malignant histiocytosis, is related to histiocytosis and lethal midline granuloma, and has symptoms including fever and malaise. An important gene associated with Fibrosarcoma of Bone is SERPINA3 (Serpin Family A Member 3), and among its related pathways/superpathways are Innate Immune System and Akt Signaling. The drugs Carboplatin and Etoposide have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and spleen, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Fibrosarcoma of Bone

Diseases related to Fibrosarcoma of Bone via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 380)
# Related Disease Score Top Affiliating Genes
1 histiocytosis 31.1 TNFRSF8 SERPINA3 CD1C CD1A
2 lethal midline granuloma 30.7 TNFRSF8 SERPINA3
3 pancytopenia 30.4 KIT CSF1 CD68
4 histiocytic sarcoma 30.4 CDKN2A CD68
5 langerhans cell sarcoma 30.2 CD68 CD1E CD1C CD1B CD1A
6 fibrous histiocytoma 30.2 SERPINA3 KIT CD68
7 leiomyosarcoma 30.0 SERPINA3 PDGFRA KIT CDKN2A
8 malignant teratoma 30.0 TNFRSF8 KIT
9 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 29.9 KIT CSF1R CSF1
10 ewing sarcoma 29.7 TNFRSF8 PDGFRA KIT KDR CDKN2A
11 leukemia, acute lymphoblastic 29.7 TNFRSF8 MYB KIT CSF1R CDKN2A
12 reticulosarcoma 29.7 TNFRSF8 SERPINA3 CD68
13 langerhans cell histiocytosis 29.6 CSF1 CD68 CD1C CD1A
14 peripheral nervous system disease 29.5 SERPINA3 KIT CDKN2A CD68
15 chronic myelomonocytic leukemia 29.5 PDGFRA KIT KDR CSF1R CSF1
16 myelodysplastic syndrome 28.7 MYB KIT KDR CSF1R CSF1 CDKN2A
17 interdigitating dendritic cell sarcoma 28.6 SERPINA3 CD1E CD1C CD1B CD1A
18 omenn syndrome 11.2
19 polymorphic reticulosis 11.1
20 fibrosarcoma 10.7
21 reticular perineurioma 10.4 PDGFRA KIT
22 virus associated hemophagocytic syndrome 10.4
23 hemophagocytic syndrome associated with an infection 10.4
24 deep leiomyoma 10.4 PDGFRA KIT
25 gastric leiomyoma 10.4 PDGFRA KIT
26 gastric leiomyosarcoma 10.4 PDGFRA KIT
27 colon leiomyosarcoma 10.4 PDGFRA KIT
28 maxillary sinus benign neoplasm 10.4 KIT CDKN2A
29 small intestine leiomyoma 10.4 PDGFRA KIT
30 osteogenic sarcoma 10.4
31 myeloid and lymphoid neoplasms associated with pdgfra rearrangement 10.4 PDGFRA KIT
32 hypereosinophilic syndrome, idiopathic 10.4 PDGFRA KIT
33 sm-ahnmd 10.3 PDGFRA KIT
34 endometrial small cell carcinoma 10.3 PDGFRA KIT
35 cutaneous solitary mastocytoma 10.3 SERPINA3 KIT
36 type c thymoma 10.3 SERPINA3 KIT
37 intratubular embryonal carcinoma 10.3 TNFRSF8 KIT
38 mixed germ cell cancer 10.3 TNFRSF8 KIT
39 pleural lipoma 10.3 TNFRSF8 KIT
40 breast malignant phyllodes tumor 10.3 SERPINA3 KIT
41 cervical adenosquamous carcinoma 10.3 PDGFRA KDR
42 trachea adenoid cystic carcinoma 10.3 MYB KIT
43 ovarian gonadoblastoma 10.3 TNFRSF8 KIT
44 embryonal sarcoma 10.3 SERPINA3 KIT
45 primary cutaneous b-cell lymphoma 10.3 KDR CDKN2A
46 carney triad 10.3 PDGFRA KIT
47 testicular malignant germ cell cancer 10.3 TNFRSF8 SERPINA3
48 lung adenoid cystic carcinoma 10.3 MYB KIT
49 uterus leiomyosarcoma 10.3 TNFRSF8 KIT
50 laryngeal small cell carcinoma 10.3 PDGFRA KIT CDKN2A

Graphical network of the top 20 diseases related to Fibrosarcoma of Bone:



Diseases related to Fibrosarcoma of Bone

Symptoms & Phenotypes for Fibrosarcoma of Bone

UMLS symptoms related to Fibrosarcoma of Bone:


fever; malaise

GenomeRNAi Phenotypes related to Fibrosarcoma of Bone according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-3 9.62 CSF1R
2 Decreased viability GR00173-A 9.62 PDGFRA
3 Decreased viability GR00221-A-1 9.62 CDKN2A CSF1R KDR KIT PDGFRA
4 Decreased viability GR00221-A-2 9.62 KDR
5 Decreased viability GR00221-A-3 9.62 CDKN2A KDR PDGFRA
6 Decreased viability GR00221-A-4 9.62 CDKN2A CSF1R KDR PDGFRA
7 Decreased viability GR00249-S 9.62 KDR PDGFRA
8 Decreased viability GR00301-A 9.62 KIT
9 Decreased viability GR00402-S-2 9.62 CSF1R PDGFRA

MGI Mouse Phenotypes related to Fibrosarcoma of Bone:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.96 CD68 CDKN2A CSF1 CSF1R KDR KIT
2 endocrine/exocrine gland MP:0005379 9.92 CDKN2A CSF1 CSF1R KIT MYB PDGFRA
3 immune system MP:0005387 9.85 CD68 CDKN2A CSF1 CSF1R KDR KIT
4 integument MP:0010771 9.61 CDKN2A CSF1 CSF1R KDR KIT MYB
5 no phenotypic analysis MP:0003012 9.28 CD68 CDKN2A CSF1 CSF1R KDR KIT

Drugs & Therapeutics for Fibrosarcoma of Bone

Drugs for Fibrosarcoma of Bone (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 93)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
2
Etoposide Approved Phase 3 33419-42-0 36462
3
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
4
Epirubicin Approved Phase 3 56420-45-2 41867
5
Dactinomycin Approved, Investigational Phase 3 50-76-0 2019 457193
6
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
7 Antibiotics, Antitubercular Phase 3
8 Anti-Infective Agents Phase 3
9 Immunosuppressive Agents Phase 3
10 Anti-Bacterial Agents Phase 3
11 Antirheumatic Agents Phase 3
12 Etoposide phosphate Phase 3
13 Alkylating Agents Phase 3
14 Tubulin Modulators Phase 3
15 Antimitotic Agents Phase 3
16
Clotrimazole Approved, Vet_approved Phase 1, Phase 2 23593-75-1 2812
17
Miconazole Approved, Investigational, Vet_approved Phase 1, Phase 2 22916-47-8 4189
18
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
19
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
20
Gemcitabine Approved Phase 2 95058-81-4 60750
21
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
22
Levoleucovorin Approved, Investigational Phase 2 68538-85-2 149436
23
Everolimus Approved Phase 1, Phase 2 159351-69-6 6442177 70789204
24
Vorinostat Approved, Investigational Phase 1, Phase 2 149647-78-9 5311
25
Sargramostim Approved, Investigational Phase 2 123774-72-1, 83869-56-1
26
Lenograstim Approved, Investigational Phase 2 135968-09-1
27
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
28
Sirolimus Approved, Investigational Phase 2 53123-88-9 6436030 5284616
29
Pegaspargase Approved, Investigational Phase 2 130167-69-0
30
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
31
Olaparib Approved Phase 2 763113-22-0 23725625
32
Vemurafenib Approved Phase 2 918504-65-1 42611257 23252090
33
Piperazine Approved, Vet_approved Phase 2 110-85-0 4837
34
Palbociclib Approved, Investigational Phase 2 571190-30-2 5005498 5330286 11431660
35
Mebendazole Approved, Vet_approved Phase 2 31431-39-7 4030
36
Pembrolizumab Approved Phase 2 1374853-91-4
37
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
38
Panobinostat Approved, Investigational Phase 2 404950-80-7 6918837
39
Ifosfamide Approved Phase 2 3778-73-2 3690
40
Mesna Approved, Investigational Phase 2 3375-50-6 598
41
rituximab Approved Phase 2 174722-31-7 10201696
42
Lenalidomide Approved Phase 2 191732-72-6 216326
43
Ipilimumab Approved Phase 1, Phase 2 477202-00-9
44
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
45
Tyrosine Approved, Investigational, Nutraceutical Phase 2 60-18-4 6057
46
Ensartinib Investigational Phase 2 1370651-20-9
47
tipifarnib Investigational Phase 2 192185-72-1 159324
48 Antifungal Agents Phase 1, Phase 2
49 Gastrointestinal Agents Phase 2
50 Antiemetics Phase 2

Interventional clinical trials:

(show all 38)
# Name Status NCT ID Phase Drugs
1 Localized Non-Rhabdomyosarcoma Soft Tissue Sarcomas Unknown status NCT00334854 Phase 3 doxorubicin hydrochloride;ifosfamide
2 MMT 95 Study For Rhabdomyosarcoma and Other Malignant Soft Tissue Tumors of Childhood Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
3 Phase I/II Trial of Torisel and Liposomal Doxorubicin in Patients With Advanced Soft Tissue and Bone Sarcomas Completed NCT00949325 Phase 1, Phase 2 temsirolimus plus liposomal doxorubicin
4 A Phase II Study Evaluating the Efficacy of Gemcitabine, Carboplatin, and Dexamethasone and Rituximab for Previously Treated Lymphoid Malignancies Completed NCT00072514 Phase 2 gemcitabine hydrochloride;carboplatin;dexamethasone
5 Pegaspargase and Methotrexate Based Regimens for Newly Diagnosed Extranodal NK/T Cell Lymphoma Completed NCT02825147 Phase 2 Pegaspargase;Methotrexate;Dexamethasone;Etoposide
6 Phase II Trial of the Aurora Kinase A Inhibitor MLN8237, in Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma Completed NCT01466881 Phase 2 Alisertib
7 A Phase I/II Clinical Trial of the mTor Inhibitor RAD001 (Everolimus) in Combination With Lenalidomide (Revlimid) for Patients With Relapsed or Refractory Lymphoid Malignancy Completed NCT01075321 Phase 1, Phase 2 everolimus;lenalidomide
8 Phase II Study of MK-2206 in Patients With Relapsed Lymphoma Completed NCT01258998 Phase 2 Akt inhibitor MK2206
9 A Phase II Study of Bendamustine (B), Etoposide (E), Dexamethasone (D), and GCSF for Peripheral Blood Hematopoietic Stem Cell Mobilization (BED) Completed NCT01110135 Phase 2 bendamustine hydrochloride;dexamethasone;etoposide
10 A Phase I/II Study of Vorinostat Plus Rituximab, Ifosphamide, Carboplatin, and Etoposide for Patients With Relapsed or Refractory Lymphoid Malignancies or Untreated T- or Mantle Cell Lymphoma Completed NCT00601718 Phase 1, Phase 2 vorinostat;ifosfamide;carboplatin;etoposide
11 A Phase I/II Study of the Histone Deacetylase (HDAC) Inhibitor LBH589 (Panobinostat) in Combination With mTOR Inhibitor RAD001 (Everolimus) in Patients With Relapsed Multiple Myeloma or Lymphoma Completed NCT00918333 Phase 1, Phase 2 panobinostat;everolimus
12 Phase II Trial of Gleevec (Formerly Known as STI571) in Patients With Soft Tissue and Bone Sarcomas: A Multi-Disciplinary Trial of the North American Sarcoma Study Group of the Connective Tissue Oncology Society Completed NCT00031915 Phase 2 imatinib mesylate
13 A Multicenter Phase II Study of Continuous Dosing of Sunitinib (Sutent®, SU11248) in Non-GIST Sarcomas Completed NCT00474994 Phase 2 sunitinib malate
14 Phase II Study of Romidepsin Plus Lenalidomide for Patients With Previously Untreated PTCL Recruiting NCT02232516 Phase 2 romidepsin;lenalidomide
15 The Efficacy and Safety of Anti-PD-1 Antibody in Combination With Pegaspargase in the Treatment of Newly Diagnosed, Stage III to IV Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type Recruiting NCT04096690 Phase 2 Pegaspargase;Anti-PD-1 monoclonal antibody
16 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol Recruiting NCT03155620 Phase 2 Ensartinib;Erdafitinib;Larotrectinib;Olaparib;Palbociclib;Samotolisib;Selpercatinib;Selumetinib Sulfate;Tazemetostat;Tipifarnib;Ulixertinib;Vemurafenib
17 A Phase 2 Study of Pembrolizumab in Patients With Histiocyte/Dendritic Cell Neoplasms and Biologically Selected Subtypes of Relapsed/Refractory Aggressive Lymphomas Recruiting NCT03316573 Phase 2 Pembrolizumab
18 A Phase II Study of the Histone Deacetylase (HDAC) Inhibitor LBH589 (Panobinostat) in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Active, not recruiting NCT01261247 Phase 2 panobinostat
19 Hypofractionated 5x5 Gy Radiotherapy With Sequential Doxorubicin and Ifosfamide-based Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall Active, not recruiting NCT03651375 Phase 2 Sequential chemotherapy - 3 courses of AI
20 A Phase II Study of Lenalidomide for Adult Histiocyte Disorders Active, not recruiting NCT02523040 Phase 2 Lenalidomide
21 A Phase 2 Study to Assess the Safety and Efficacy of Cobimetinib in Refractory Langerhans Cell Histiocytosis, LCH-Associated Neurodegenerative Disease, and Other Histiocytic Disorders. Not yet recruiting NCT04079179 Phase 2 Cobimetinib
22 A PHASE I/II STUDY OF INTRATUMORAL INJECTION OF IPILIMUMAB IN COMBINATION WITH LOCAL RADIATION IN MELANOMA, NON-HODGKIN LYMPHOMA AND COLORECTAL CARCINOMA Terminated NCT01769222 Phase 1, Phase 2
23 A Phase II Study Investigating Treatment of Post-Allogeneic Transplant Progression or Relapse of CLL/SLL/PLL or NHL With Lenalidomide Alone or With Rituximab Terminated NCT01419795 Phase 2 lenalidomide
24 Phase I Study of AR-42 in Relapsed Myeloma, Chronic Lymphocytic Leukemia, and Lymphoma Completed NCT01129193 Phase 1 AR-42
25 Phase I Dose-Escalation Study of Azacitidine (Vidaza) and Bortezomib (Velcade) in T-Cell Lymphoma Completed NCT01129180 Phase 1 azacitidine;bortezomib
26 Phase I Study of Carfilzomib for the Treatment of T-Cell Lymphoma Completed NCT01336920 Phase 1 carfilzomib
27 Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors Completed NCT01748721 Phase 1
28 Phase I Trial of Fludarabine and Methoxyamine (TRC102) for Relapsed or Refractory Hematologic Malignancies Completed NCT01658319 Phase 1 fludarabine phosphate;methoxyamine
29 A Phase I Trial of Postoperative Radiation With Dose-Escalation of A Cox-2 Inhibitor, Celebrex™ (CELECOXIB) in Patients With Soft Tissue Sarcoma of the Extremity Completed NCT00450736 Phase 1 celecoxib
30 A Phase I Trial of 5Azacitidine and Suberoylanilide Hydroxamic Acid in Patients With Metastatic or Locally Recurrent Nasopharyngeal Carcinoma and Nasal NK-T Cell Lymphoma Active, not recruiting NCT00336063 Phase 1 Azacitidine;Vorinostat
31 A Phase I Study of PXD101 in Combination With 17-AAG in Advanced Malignancies Terminated NCT00354185 Phase 1 tanespimycin;belinostat
32 A Phase I Study of the Combination of Lenalidomide With the Histone Deacetylase Inhibitor, Vorinostat in Hodgkin and Non Hodgkin's Lymphoma Terminated NCT01116154 Phase 1 lenalidomide;vorinostat
33 A Phase I Study Evaluating Escalating Doses of 90Y-BC8-DOTA (Anti-CD45) Antibody Followed by Autologous Stem Cell Transplantation for Relapsed or Refractory Lymphoid Malignancies Terminated NCT01678443 Phase 1
34 Induction of Mixed Hematopoietic Chimerism in Older Patients With B-Cell Malignancies and in Selected Other Diseases, Using Low Dose TBI , PBSC Infusion and Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil to be Followed by Donor Lymphocyte Infusion: A Pilot Study. Completed NCT00003196 chemotherapy;cyclosporine;mycophenolate mofetil
35 A Pilot Feasibility Trial of the Tolerability of Oral Salvia Hispanica and Its Effect on Blood Fatty Acids and Stool Microbiome in Patients With Treated Non-Hodgkin Lymphoma Completed NCT02652715
36 Genetic Study of Patients and Families With Diaphyseal Medullary Stenosis With Malignant Fibrous Histiocytoma of the Bone Completed NCT00007046
37 AUTOLOGOUS TRANSPLANTATION AND STEM CELL BASED-GENE THERAPY FOR THE TREATMENT OF HIV-ASSOCIATED LYMPHOMA Withdrawn NCT01769911 carmustine;cytarabine;melphalan;etoposide;O6-benzylguanine
38 Prevention of Mucositis in Children With AES-14 (IND#36978), a Glutamine Based Oral Care Regimen, for Patients Diagnosed With Solid Tumors: A Randomized Placebo-Controlled Clinical Study Withdrawn NCT00334984 glutamine

Search NIH Clinical Center for Fibrosarcoma of Bone

Genetic Tests for Fibrosarcoma of Bone

Anatomical Context for Fibrosarcoma of Bone

MalaCards organs/tissues related to Fibrosarcoma of Bone:

40
Bone, Bone Marrow, Spleen, Skin, Lymph Node, Myeloid, Small Intestine

Publications for Fibrosarcoma of Bone

Articles related to Fibrosarcoma of Bone:

(show top 50) (show all 885)
# Title Authors PMID Year
1
Epithelial membrane antigen (EMA) or MUC1 expression in monocytes and monoblasts. 61 54
14555387 2003
2
CD30 antigen in non-Hodgkin's lymphoma. 61 54
8055109 1994
3
Monocyte/macrophage system and malignancies. 61 54
8084313 1994
4
Modulation of c-myc, c-myb, c-fos, c-sis and c-fms proto-oncogene expression and of CSF-1 transcripts and protein by phorbol diester in human malignant histiocytosis DEL cell line with 5q 35 break point. 54 61
8352523 1993
5
[Distribution of three proteinases in tumor cells of malignant histiocytosis]. 54 61
2279308 1990
6
Sclerosing epithelioid fibrosarcoma of bone: morphological, immunophenotypical, and molecular findings of 9 cases. 61
33084978 2021
7
Histiocytosis and Neoplasms of Macrophage-Dendritic Cell Lineages: Multimodality Imaging with Emphasis on PET/CT. 61
33606566 2021
8
Canine tonsillar neoplasia and tonsillar metastasis from various primary neoplasms. 61
32352191 2020
9
Clinical and molecular characterization of primary sclerosing epithelioid fibrosarcoma of bone and review of the literature. 61
31675134 2020
10
The Management of Head and Neck Sarcoma. 61
31934973 2020
11
[Histiocytosis in the dermatological context of the new classification]. 61
31414152 2019
12
Novel NTRK3 Fusions in Fibrosarcomas of Adults. 61
30520818 2019
13
Albumin fusion improves the pharmacokinetics and in vivo antitumor efficacy of canine interferon gamma. 61
30639219 2019
14
KRAS mutation in secondary malignant histiocytosis arising from low grade follicular lymphoma. 61
30322385 2018
15
Peroxiredoxin 1 (PRDX1) Suppresses Progressions and Metastasis of Osteosarcoma and Fibrosarcoma of Bone. 61
29908016 2018
16
Alemtuzumab-based therapy for Secondary Malignant Histiocytosis arising from Pre-B-ALL. 61
29264111 2018
17
Histiocytic proliferations. 61
27720561 2016
18
BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System. 61
27207774 2016
19
Mediastinal Germ Cell Tumor-associated Histiocytic Proliferations Treated With Thalidomide Plus Chemotherapy Followed by Alemtuzumab-containing Reduced Intensity Allogeneic Peripheral Blood Stem Cell Transplantation: A Case Report. 61
26765473 2016
20
Challenges in the differential diagnosis of interdigitating dendritic cell sarcoma of intraparotid lymph node vs. metastatic malignant melanoma with unknown primary site. 61
25722315 2015
21
Primary sclerosing epithelioid fibrosarcoma of bone: analysis of a series. 61
24921641 2014
22
Pediatric histiocytoses in the United States: incidence and outcomes. 61
24766726 2014
23
Causes of death and the impact of histiocytic sarcoma on the life expectancy of the Dutch population of Bernese mountain dogs and Flat-coated retrievers. 61
24231621 2013
24
Selection for Evi1 activation in myelomonocytic leukemia induced by hyperactive signaling through wild-type NRas. 61
22847614 2013
25
[Mucinous cystadenomas of the liver]. 61
23745339 2013
26
Malignant fibrous histiocytoma and fibrosarcoma of bone: a re-assessment in the light of currently employed morphological, immunohistochemical and molecular approaches. 61
23001328 2012
27
A retrospective analysis of pathological and clinical diagnoses: report of 240 pediatric autopsies. 61
22273458 2012
28
Bisphosphonates significantly increase the activity of doxorubicin or vincristine against canine malignant histiocytosis cells. 61
22236140 2012
29
Cytophagic histiocytic panniculitis with haemophagocytosis in a patient with familial multiple lipomatosis and review of the literature. 61
21732050 2012
30
[Primary malignant bone tumors]. 61
22130624 2011
31
Array comparative genomic hybridization reveals frequent alterations of G1/S checkpoint genes in undifferentiated pleomorphic sarcoma of bone. 61
21254299 2011
32
Quantitative PCR and immunohistochemical analyses of HMGB1 and RAGE expression in canine disseminated histiocytic sarcoma (malignant histiocytosis). 61
21617208 2011
33
Macrophage activation syndrome in malaria. 61
19593570 2010
34
Heterogeneity in a mouse model of histiocytosis: transformation of Langerin+ dendritic cells, macrophages, and precursors. 61
20145199 2010
35
Evaluation of liposomal clodronate for treatment of malignant histiocytosis in dogs. 61
19760220 2010
36
Malignant histiocytosis and other causes of death in Bernese mountain dogs in Denmark. 61
20154310 2010
37
Frequent deletion of CDKN2A and recurrent coamplification of KIT, PDGFRA, and KDR in fibrosarcoma of bone--an array comparative genomic hybridization study. 61
19862822 2010
38
Analysis of histiocytosis deaths in the US and recommendations for incidence tracking. 61
21688746 2010
39
[Malignant histiocytosis in a neonate]. 61
19695191 2009
40
Epidemiology, pathology, and genetics of histiocytic sarcoma in the Bernese mountain dog breed. 61
19531730 2009
41
Malignant histiocytosis of the skin: a case report and review of the literature. 61
21886719 2009
42
MR imaging of histiocytic sarcoma of the canine brain. 61
19400464 2009
43
Secondary tumoural valvulopathy in a dog. 61
19457774 2009
44
Hematopoietic neoplasias in horses: myeloproliferative and lymphoproliferative disorders. 61
24833969 2009
45
Morphological characterisation of malignant histiocytosis in a cat. 61
19085873 2008
46
Contrast harmonic imaging characterization of canine splenic lesions. 61
18681923 2008
47
[Clinicopathological analysis of 141 pediatric autopsy cases]. 61
19099750 2008
48
Canine histiocytic diseases. 61
18576276 2008
49
[Malignant histiocytosis-like B-cell lymphoma of liver: report of a case]. 61
18509992 2008
50
Secondary malignant neoplasms after intensive treatment of relapsed acute lymphoblastic leukaemia in childhood. 61
17981026 2008

Variations for Fibrosarcoma of Bone

Expression for Fibrosarcoma of Bone

Search GEO for disease gene expression data for Fibrosarcoma of Bone.

Pathways for Fibrosarcoma of Bone

Pathways related to Fibrosarcoma of Bone according to GeneCards Suite gene sharing:

(show all 21)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.84 TNFRSF8 SERPINA3 PDGFRA KIT CSF1R CSF1
2
Show member pathways
13.22 TNFRSF8 PDGFRA KIT KDR CSF1R CSF1
3
Show member pathways
13.12 TNFRSF8 PDGFRA KIT KDR CSF1R CSF1
4
Show member pathways
12.68 PDGFRA MYB KIT KDR CSF1R CSF1
5 12.6 PDGFRA KIT KDR CSF1R CSF1
6
Show member pathways
12.55 PDGFRA KIT KDR CSF1R CSF1
7 11.99 CD1E CD1C CD1B CD1A
8 11.9 CD1C CD1B CD1A
9 11.88 PDGFRA KIT KDR CSF1R
10 11.64 MYB KIT CSF1R
11 11.62 KIT CSF1 CD68 CD1C
12 11.56 PRDX1 CD1E CD1C CD1B CD1A
13 11.42 PDGFRA KIT KDR
14 11.35 KIT CSF1R CSF1
15 11.32 KDR CSF1R CSF1
16
Show member pathways
11.23 KDR CSF1R CSF1
17 11.22 KIT CSF1R CSF1 CD1C CD1A
18 11.16 KIT CSF1R CSF1 CD1E CD1C CD1B
19
Show member pathways
11.03 PDGFRA KIT KDR
20 10.86 PDGFRA KIT KDR CSF1R CSF1
21 10.79 CSF1 CD68

GO Terms for Fibrosarcoma of Bone

Cellular components related to Fibrosarcoma of Bone according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of membrane GO:0016021 10.03 TNFRSF8 PDGFRA MYB KIT KDR CSF1R
2 integral component of plasma membrane GO:0005887 9.95 PDGFRA KIT KDR CSF1R CD1E CD1C
3 extracellular space GO:0005615 9.92 SERPINA3 PRDX1 KIT CSF1 CD1E CD1C
4 endosome membrane GO:0010008 9.73 CD68 CD1C CD1B CD1A
5 receptor complex GO:0043235 9.67 PDGFRA KIT KDR CSF1R
6 endosome GO:0005768 9.63 KDR CD68 CD1E CD1C CD1B CD1A
7 external side of plasma membrane GO:0009897 9.1 PDGFRA KIT CD1E CD1C CD1B CD1A
8 CSF1-CSF1R complex GO:1990682 8.96 CSF1R CSF1

Biological processes related to Fibrosarcoma of Bone according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 phosphorylation GO:0016310 9.97 PDGFRA KIT KDR CSF1R CDKN2A
2 immune system process GO:0002376 9.97 CSF1R CSF1 CD1E CD1C CD1B CD1A
3 positive regulation of cell proliferation GO:0008284 9.92 PDGFRA KIT KDR CSF1R CSF1
4 inflammatory response GO:0006954 9.9 SERPINA3 KIT CSF1R CSF1
5 positive regulation of cell migration GO:0030335 9.8 PDGFRA KIT KDR CSF1R CSF1
6 regulation of cell shape GO:0008360 9.79 KIT KDR CSF1R
7 protein autophosphorylation GO:0046777 9.78 PDGFRA KIT KDR CSF1R
8 peptidyl-tyrosine phosphorylation GO:0018108 9.73 PDGFRA KIT KDR CSF1R
9 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.72 PDGFRA KIT KDR
10 positive regulation of kinase activity GO:0033674 9.67 PDGFRA KIT KDR CSF1R
11 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.65 PDGFRA KIT KDR CSF1R CSF1
12 hematopoietic progenitor cell differentiation GO:0002244 9.62 PDGFRA KIT KDR CSF1R
13 macrophage differentiation GO:0030225 9.61 CSF1R CSF1
14 regulation of actin cytoskeleton reorganization GO:2000249 9.59 PDGFRA CSF1R
15 embryonic hemopoiesis GO:0035162 9.58 KIT KDR
16 positive regulation of macrophage chemotaxis GO:0010759 9.58 CSF1R CSF1
17 positive regulation of phospholipase C activity GO:0010863 9.56 PDGFRA KIT
18 somatic stem cell division GO:0048103 9.54 KIT CDKN2A
19 microglial cell proliferation GO:0061518 9.51 CSF1R CSF1
20 macrophage colony-stimulating factor signaling pathway GO:0038145 9.46 CSF1R CSF1
21 positive regulation of T cell mediated cytotoxicity GO:0001916 9.46 CD1E CD1C CD1B CD1A
22 antigen processing and presentation, exogenous lipid antigen via MHC class Ib GO:0048007 9.26 CD1E CD1C CD1B CD1A
23 antigen processing and presentation, endogenous lipid antigen via MHC class Ib GO:0048006 8.92 CD1E CD1C CD1B CD1A

Molecular functions related to Fibrosarcoma of Bone according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 kinase activity GO:0016301 9.83 PDGFRA KIT KDR CSF1R CDKN2A
2 protein tyrosine kinase activity GO:0004713 9.62 PDGFRA KIT KDR CSF1R
3 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.56 PDGFRA KIT KDR CSF1R
4 lipopeptide binding GO:0071723 9.46 CD1E CD1C CD1B CD1A
5 vascular endothelial growth factor-activated receptor activity GO:0005021 9.4 PDGFRA KDR
6 vascular endothelial growth factor binding GO:0038085 9.37 PDGFRA KDR
7 exogenous lipid antigen binding GO:0030884 9.26 CD1E CD1C CD1B CD1A
8 endogenous lipid antigen binding GO:0030883 8.92 CD1E CD1C CD1B CD1A

Sources for Fibrosarcoma of Bone

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....